Abstract:Background & aims: Growing evidence suggests an increased prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in the context of immune-mediated inflammatory diseases (IMIDs). We aimed to clinically and mechanistically characterize steatotic liver disease (SLD) in a prospective cohort of patients with IMID compared to controls. Methods: Cross-sectional, case-control study including a subset of patients with IMID. Controls from the general population were age-, sex-, type 2 diabetes-, and BMI-matched at a 1:2 ratio. SLD was established using controlled attenuation parameter. Liver biopsies were obtained when significant liver fibrosis was suspected. Total RNA was extracted from freshly frozen cases and analyzed by RNA-seq. Differential gene expression was performed with 'limma-voom'. Gene set-enrichment analysis was performed using the fgsea R package with a preranked "limma t-statistic" gene list. Results: A total of 1,456 patients with IMID and 2,945 controls were included. Advanced SLD (liver stiffness measurement ≥9.7 kPa) (13.46% vs. 3.79%; p <0.001) and advanced MASLD (12.8% vs. 2.8%; p <0.001) prevalence were significantly higher among patients with IMID than controls. In multivariate analysis, concomitant IMID was an independent, and the strongest, predictor of advanced SLD (adjusted odds ratio 3.318; 95% CI 2.225-4.947; p <0.001). Transcriptomic data was obtained in 109 patients and showed 87 significant genes differentially expressed between IMID-MASLD and control-MASLD. IMID-MASLD cases displayed an enriched expression of genes implicated in pro-tumoral activities or the control of the cell cycle concomitant with a negative expression of genes related to metabolism. Conclusions: The prevalence of advanced SLD and MASLD is disproportionately elevated in IMID cohorts. Our findings suggest that IMIDs may catalyze a distinct MASLD pathway, divergent from classical metabolic routes, highlighting the need for tailored clinical management strategies. Impact and implications: The prevalence of steatotic liver disease with advanced fibrosis is increased in patients with immune-mediated inflammatory diseases, independent of classic metabolic risk factors or high-risk alcohol consumption. Transcriptomic analysis revealed a unique gene expression signature associated with cellular activities that are compatible with a liver condition leading to an accelerated and aggressive form of steatotic liver disease. Our findings underscore the importance of heightened screening for advanced liver disease risk across various medical disciplines overseeing patients with immune-mediated inflammatory diseases.

Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease

Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update

Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease

Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-associated steatotic liver disease

Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD

A functional genomic framework to elucidate novel causal metabolic dysfunction-associated fatty liver disease genes

Cardiometabolic Phenotype Linked to Fibrosis and Mortality in Metabolic Dysfunction-Associated Steatotic Liver Disease

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD

Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?

Identification of signature gene set as highly accurate determination of MASLD progression

Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment

Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver‐Related Events in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study

Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

From Pathogenesis to Current Therapeutic Options